Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain NBIX message board posts where the ticker symbol NBIX has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest NBIX SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-040121 Size: 22 KB
2018-06-29
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-039022 Size: 8 KB
2018-06-21
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-038096 Size: 5 KB
2018-06-15
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-038093 Size: 18 KB
2018-06-15
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-037379 Size: 5 KB
2018-06-13
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-035925 Size: 5 KB
2018-06-05
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-18-006166 (34 Act)  Size: 10 KB
2018-06-05 000-22705
18880313
8-K  Documents Current report, items 5.02, 5.07, and 9.01
Acc-no: 0001193125-18-178679 (34 Act)  Size: 231 KB
2018-05-30 000-22705
18868950
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-033640 Size: 5 KB
2018-05-25
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-033638 Size: 5 KB
2018-05-25
More NBIX SEC Filings


Related news from
Tue, 10 Jul 2018
20:01:00 +0000
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2018 Financial Results
Conference Call and Webcast Scheduled for Tuesday, July 31 SAN DIEGO , July 10, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report second quarter financial ...
Mon, 09 Jul 2018
18:49:29 +0000
Why Analysts are Mostly Positive On Acceleron Pharma
After Acceleron’s and Celgene’s (CELG) June 28 announcement of the Phase 3 MEDALIST trial results, Acceleron stock started rising, recording ~42.79% growth on June 29 to close at $48.52. Celgene and Acceleron Pharma conducted the MEDALIST trial to evaluate the safety and efficacy of luspatercept for the treatment of individuals with myelodysplastic syndrome and chronic anemia who are not eligible or are intolerant to erythropoietin-stimulating agents.
Sat, 07 Jul 2018
12:02:36 +0000
See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Thu, 05 Jul 2018
11:25:00 +0000
Free Technical Reports on Novavax and Three Additional Biotech Equities
WallStEquities.com has initiated research reports on the following Biotechnology stocks: Nabriva Therapeutics PLC (NASDAQ: NBRV), Neurocrine Biosciences Inc. (NASDAQ: NBIX), Novavax Inc. (NASDAQ: NVAX), and Novo Nordisk A/S (NYSE: NVO). All you have to do is sign up today for this free limited time offer by clicking the link below.
Wed, 27 Jun 2018
10:01:00 +0000
3 Biotech Stocks With Major Potential Catalysts in July
FDA approvals next month could be huge for these biotech stocks.
Wed, 20 Jun 2018
11:52:00 +0000
5 Stocks That Are Screaming Buys Right Now
Here we used TipRanks' stock screener to pinpoint the most compelling stocks right now. The Street is buzzing about Neurocrine's Ingrezza drug, the first FDA-approved treatment for adults with tardive dyskinesia. On its first quarter earnings call, Neurocrine updated the Street with respect to ongoing market penetration for Ingrezza.
Tue, 12 Jun 2018
12:26:53 +0000
Versartis Stock and Its Consistent Rise in the Week Ended June 8
Versartis (VSAR) stock rose 48.3% in the week of June 1–8. Versartis had consistent growth during the week, with 6.9% and 9.7% growth on June 4 and June 5, respectively. VSAR stock has risen ~50.9% over the last month. On June 4, Versartis entered into a merger agreement with Aravive Biologics.
Fri, 08 Jun 2018
20:56:00 +0000
Chief Executive Officer of Neurocrine Biosciences, Kevin Gorman, Ph.D., Named EY Entrepreneur Of The Year® 2018 San Diego
SAN DIEGO, June 8, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX), a San Diego based biotechnology company focused on neurological and endocrine related disorders, is proud to announce that Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences, received the Entrepreneur Of The Year® 2018 Award in the Life Sciences category in San Diego . The EY awards program recognizes entrepreneurs whose ingenuity, spirit of innovation and discipline have driven their companies' success, transformed their industries and made a positive impact on their communities.
Sat, 02 Jun 2018
20:34:29 +0000
What You Must Know About Neurocrine Biosciences Inc’s (NASDAQ:NBIX) Financial Strength
Mid-caps stocks, like Neurocrine Biosciences Inc (NASDAQ:NBIX) with a market capitalization of US$8.60B, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-capRead More...
Tue, 22 May 2018
11:00:00 +0000
Free Technical Insights on OPKO Health and Three Other Biotech Stocks
Stock Research Monitor: NBIX, NVAX, and ONTX LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want a free Stock Review on OPK sign up now at www.wallstequities.com/registration . On Monday, benchmark US ...
Mon, 14 May 2018
12:25:00 +0000
Factors of Influence in 2018, Key Indicators and Opportunity within Fred's, Nexstar Broadcasting Group, CNO Financial Group, Neurocrine Biosciences, Kosmos Energy, and Loews — New Research Emphasizes Economic Growth
NEW YORK, May 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fred's, ...
Wed, 09 May 2018
20:01:00 +0000
Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference
Live Audio Webcast Will be on May 15, 2018 SAN DIEGO , May 9, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Bank of America Merrill Lynch 2018 Healthcare Conference ...
Wed, 09 May 2018
10:00:00 +0000
3 Top Biotech Stocks to Buy in May
Looking for a few timely buys in the biotech space? Give these gems a closer look.
Tue, 08 May 2018
18:00:00 +0000
Neurocrine Biosciences Presents New Quality of Life Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia in Patients Treated with Antipsychotics
SAN DIEGO, May 8, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced new data from RE-KINECT, the largest real-world screening study to date of patients with clinician-confirmed possible tardive dyskinesia (TD), providing valuable insight into the impact of involuntary movements on the quality of life of patients taking antipsychotic medication. TD is a condition that is characterized by uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face, which may be disruptive and negatively impact patients.
Thu, 03 May 2018
14:15:00 +0000
NBIX: Strong INGREZZA® Sales Continue in 1Q18; Expanding Sales Team for Future Growth
By David Bautz, PhD NASDAQ:NBIX INGREZZA® Launch Continues to go Well On April 30, 2018, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced financial results for the first quarter of 2018 and provided ...
Wed, 02 May 2018
20:14:00 +0000
Neurocrine Biosciences to Present New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2018 American Psychiatric Association Annual Meeting
SAN DIEGO, May 2, 2018 /PRNewswire/ -- Neurocrine Biosciences Inc. (NBIX) today announced that it will present new data from RE-KINECT, the largest real-world screening study to date of patients with clinician confirmed possible tardive dyskinesia (TD). This study is designed to better understand the potentially broad reaching impact of symptoms of possible TD on patients treated with antipsychotic medications.
Wed, 02 May 2018
17:52:28 +0000
Edited Transcript of NBIX earnings conference call or presentation 30-Apr-18 9:00pm GMT
Q1 2018 Neurocrine Biosciences Inc Earnings Call
Tue, 01 May 2018
11:51:51 +0000
Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on April 30) CareDx Inc (NASDAQ: CDNA ) Eleven Biotherapeutics Inc (NASDAQ: ...



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "This is a site for sharing information about the atypical investments that the majority of investors have not discovered. It is about finding the next value/growth sector/investment before all the major houses on the Street are recommending it." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards